Get the Stockscreener App
209.03
1.96%
4.01
Pre-market:
208.91
-0.12
-0.06%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $209.03, with a volume of 12.60M.
It is up +1.96% in the last 24 hours and up +13.67% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
See More
Previous Close:
$205.02
Open:
$205.12
24h Volume:
12.60M
Relative Volume:
2.30
Market Cap:
$369.01B
Revenue:
$56.33B
Net Income/Loss:
$4.28B
P/E Ratio:
87.10
EPS:
2.4
Net Cash Flow:
$17.83B
1W Performance:
+3.44%
1M Performance:
+13.67%
6M Performance:
+6.48%
1Y Performance:
+18.73%
1-Day Range:
$204.41
$209.60
1-Week Range:
$201.28
$209.60
52-Week Range:
$153.58
$209.60
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
209.03 | 369.01B | 56.33B | 4.28B | 17.83B | 2.40 |
|
LLY
Lilly Eli Co
|
920.63 | 874.97B | 45.04B | 10.59B | 414.30M | 11.71 |
|
NVO
Novo Nordisk Adr
|
90.65 | 402.40B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
JNJ
Johnson Johnson
|
165.02 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
MRK
Merck Co Inc
|
92.25 | 251.88B | 64.17B | 17.12B | 18.10B | 6.73 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
AbbVie pays Gubra $350m upfront to enter obesity field - pharmaphorum
AbbVie Enters License Deal With Gubra to Develop Obesity Treatment -March 03, 2025 at 04:01 am EST - Marketscreener.com
Gubra surges on AbbVie partnership for obesity treatment - TradingView
AbbVie, Gubra Sign License Deal to Develop Amylin Analog for Obesity Treatment -March 03, 2025 at 02:12 am EST - Marketscreener.com
AbbVie and Gubra Announces License Agreement to Develop an Amylin Analog for the Treatment of Obesity - Marketscreener.com
AbbVie Inc. (ABBV): Among the Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
AbbVie Inc. (NYSE:ABBV) SVP Sells $3,853,399.04 in Stock - MarketBeat
US Bancorp DE Sells 24,245 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Sold by Mutual of America Capital Management LLC - MarketBeat
SVB Wealth LLC Invests $45.76 Million in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Bought by Illinois Municipal Retirement Fund - MarketBeat
Lake Street Advisors Group LLC Grows Stake in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Longbow Finance SA Has $6.98 Million Stock Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie (NYSE:ABBV) Shares Up 0.4%Still a Buy? - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Sold by Nelson Capital Management LLC - MarketBeat
DMKC Advisory Services LLC Buys Shares of 1,335 AbbVie Inc. (NYSE:ABBV) - MarketBeat
Exchange Capital Management Inc. Purchases Shares of 1,587 AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie (NYSE:ABBV) Trading Up 0.3%Should You Buy? - MarketBeat
AbbVie Inc. (NYSE:ABBV) EVP Timothy J. Richmond Sells 29,917 Shares - MarketBeat
AbbVie Inc. (NYSE:ABBV) Stock Position Lifted by Trifecta Capital Advisors LLC - MarketBeat
AbbVie (NYSE:ABBV) Sets New 52-Week HighShould You Buy? - MarketBeat
AbbVie SVP Buckbee sells $3.85 million in stock - Investing.com India
AbbVie EVP Richmond sells $6.07 million in stock - Investing.com
Aldeyra Therapeutics, Inc. SEC 10-K Report - TradingView
Europe poised to OK another use for AbbVie's Rinvoq - Crain's Chicago Business
AbbVie Stock: Is ABBV Outperforming the Healthcare Sector? - Nasdaq
AbbVie's Next Big Moneymaker? This Drug Just Took a Huge Step Toward Approval - Yahoo Finance
OPZELURA Continues to Revolutionize Dermatology Market with Strong Market Uptake | DelveInsight - GlobeNewswire Inc.
AbbVie stock soars to all-time high, reaching $207.34 - Investing.com
CHMP recommends AbbVie’s Rinvoq be approved for adult GCA - Pharmaceutical Technology
AbbVie Stock: Is ABBV Outperforming The Healthcare Sector? - Barchart
AbbVie closes on Rinvoq approval in inflamed artery disease - pharmaphorum
AbbVie Inc. (NYSE:ABBV) Stock Holdings Decreased by Anchor Capital Advisors LLC - MarketBeat
AbbVie Gets CHMP Backing of Rinvoq in Giant Cell Arteritis - MarketWatch
Commonwealth Retirement Investments LLC Has $8.69 Million Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Pine Valley Investments Ltd Liability Co Raises Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
FourThought Financial Partners LLC Takes $3.20 Million Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Receives Positive Opinion on Giant Cell Arteritis Therapy From European Medicines Agency - Marketscreener.com
Y Intercept Hong Kong Ltd Acquires New Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
U.S. Acellular Dermal Matrices Market Projected To Witness Substantial Growth, 2025-2032: AbbVie Inc., Johnson - EIN News
Asset Advisors Investment Management LLC Lowers Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis - PR Newswire
RWC Asset Management LLP Takes Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
IFP Advisors Inc Buys 4,928 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
ABBV: 3 Healthcare Stocks Tackling America’s Biggest Medical Challenges - StockNews.com
Mustang Bio exits Worcester facility, sells assets to AbbVie By Investing.com - Investing.com South Africa
Mustang Bio exits Worcester facility, sells assets to AbbVie - Investing.com
Alecta Tjanstepension Omsesidigt Makes New $186.43 Million Investment in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Motiv8 Investments LLC Raises Stock Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Oppenheimer Asset Management Inc. Lowers Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
New York Life Investment Management LLC Raises Stake in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):